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PD-L1 expression on tumor cells and immune cells could predict re-
ponse to immunotherapy [1] . However, tiny biopsy samples can result
n false-negative PD-L1 evaluation [2] . Herein, we describe the accurate
dentification of PD-L1 on peripheral blood myeloid derived suppressor
ells (MDSCs). 
A 72-year-old male, never-smoker, was diagnosed with recurrent
ung adenocarcinoma, PD-L1 negative ( 22C3), without actionable mu-
ations. The patient was treated with nivolumab, and paclitaxel. Af-
er progression, he was re-treated with nivolumab plus glutaminase in-
ibitor until persistence of adrenal and distant lymph node metastasis
as observed. Atezolizumab plus T cell immunoglobulin mucin-domain
ontaining-3 (TIM3) inhibitor was administered as third line therapy.
he patient completed 11 cycles. Afterwards, the left adrenal gland was
rradiated and a muscle metastasis in the left gluteus was resected. Tar-
eted Next Generation Sequencing (NGS) in metastatic tissue and blood
ere negative for actionable alterations. The patient received further
reatment with a novel anti-PD-L1 (PDR001) combination. However,
urther progression was identified with widespread bone and lymph
ode metastases (More details in Supplementary Figure 1). Peripheral
lood samples were serially collected before and after immunotherapy
or the assessment of MDSCs and PD-L1 expression by multi-color flow
ytometry. 
Prior to immunotherapy (day 0), peripheral blood smear analy-
is showed mostly neutrophils and monocytes, and lymphocytes were
learly reduced (Supplementary Fig. 2A and B). Hematology analysis
howed a decreased number of lymphocytes (5.5%), and a marked in-
rease in monocytes (13%) and neutrophils (80.2%). At initial assess-
ent, red-cell count, hemoglobin and hematocrit showed decreased con-
entrations. White-cell analysis by multi-color flow cytometry showed
hat PD-L1 was dramatically increased after Phorbol 12-myristate 13-
cetate (PMA) stimulation. Peripheral blood cells were mostly PD-L1 +
DSCs (81.50% polymorphonuclear PMN-MDSCs and 7.74% monocytic
-MDSCs) ( Fig. 1 B). 
Surprisingly, non-stimulated cells expressed undetectable levels of
D-L1, as shown by the flow cytometry method when DMSO was used
 Fig. 1 A). This suggests that PD-L1 displays some variation of spatial
onformation [3] in response to PMA stimulation, which may confer a
ritical enhancement in binding affinity. This variability may help tottps://doi.org/10.1016/j.tranon.2020.100969 
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 http://creativecommons.org/licenses/by-nc-nd/4.0/ ) xplain the different response to targeted immunotherapy against PD-
1, also suggesting that phenotypic characterization is not sufficient to
dentify MDSCs and an additional proof of the immunosuppressive func-
ion is needed. PD-L1 was studied in a total of 5 samples, before and after
mmunotherapy (day 0, 1, 4, 6 and 8) showing differences in PD-L1 ex-
ression (Supplemental Fig. 3 and Supplemental Figure 4A) as well as in
he relative number of MDSCs (Supplemental Figure 4B). Merging all to-
ether into a single FCS file using a process called concatenation, periph-
ral blood samples were effectively compared ( Fig. 1 C and D). Dimen-
ionality reduction was performed on the concatenated data set. After
MA stimulation, PD-L1 + cells were displayed based on the expression
f 6 markers using t-SNE (t-distributed stochastic neighbor embedding)
isualization. The axes show dimensionless values that were assigned
o individual cells by the t-SNE algorithm, which places PD-L1 + MDSCs
hat have similar expression profiles close to one another. Eliminating
DSCs by promoting PD-L1 stabilized unfolded states on both PMN- and
-MDSCs could improve immunotherapy efficacy. High frequency of
MN-MDSCs [4] is an adverse prognostic factor in lung [5] and head and
eck cancer [ 6 , 7 ]. This conformational change may be associated with
 PD-L1 immunoregulatory mechanism that affects therapies targeting
he PD-1/PD-L1 checkpoint. Conformational changes, accumulation,
xpansion, and survival of MDSCs require research for PD-L1 unfolding.
onitoring peripheral blood MDSCs and identification of drugs with
MA-like effects is highly warranted. In view of these conformational
roperties, analysis of accumulation, expansion and survival of patho-
ogical immunosuppressive MDSCs could help to better understand and
vercome the mechanisms of immunotherapy resistance, by developing
ew treatment strategies aimed at promoting PD-L1 stabilized unfolded
tates. Altogether, our findings may indicate the clinical relevance of
eripheral blood MDSCs assessment and immunosuppressive pattern,
s well as the need to find compounds that by themselves exhibit a
MA-like effect aimed at abrogating MDSCs. Limitations of this study
nclude the enrollment of only one patient and a short follow–up period,
ecause exitus occurred after a few days of analysis. Important research
ust be done to elucidate the mechanism by which PD-L1 is translo-
ated and the clinical relevance to those patients with higher PD- L1
old-change. Future experiments will attempt to further dissect to what
egree stimulation increases PD-L1 expression on MDSCs and how this
nformation can be translated into benefit for immunotherapy. The fea-
ibility of determining PD-L1 expression on MDSCs and its potential use
s a biomarker to determine treatment response is promoting new ways
o study cancer, particularly in the promising area of immunotherapy. ovember 2020 
ticle under the CC BY-NC-ND license 
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Fig. 1. Evaluation of PD-L1 expression and clustering analysis in terms of cell number and antigenic density comparisons across immunotherapy. 
Evaluation of PD-L1 fold-increase of a 72-year-old male, a lifetime non-smoker, diagnosed with lung adenocarcinoma in 2014 the day before immunotherapy 
administration (day 0) and day 1, 4, 6 and 8 before immunotherapy. Panel A and B show a representative peripheral blood analysis on day 0stimulated for 5 min 
at 37 °C with PMA. Numbers in regions R5 to R7 indicate gated cell counts. Fold-change was calculated as the ratio between stimulated PD-L1 + MDSCs and non- 
stimulated PD-L1 + cells. PMN-MDSCs were identified by their expression of PD-L1 together with CD33 + CD11b high HLA-DR − /low and M-MDSCs were identified by 
their expression of PD-L1 together with CD33 high CD11b + HLA-DR − /low . The MDSCs PD-L1 + population was calculated over the total number of acquired leukocytes, 
identified in the DCV + gate (R1), in the single cell gate (R2) and in the 7-AAD- gate (R3) (data not shown). Changes in PD-L1 expression after PMA treatment found 
a 191-fold increase after stimulation (Panel B), compared with non-stimulated cells (Panel A), suggesting that fold-change in PD-L1 appears to have an important 
regulatory factor that may relate to differences in underlying mechanisms within patients. 
Merging all measurements together into a single FCS file using a process called concatenation, peripheral blood samples obtained before and after immunotherapy 
treatment were effectively compared. Dimensionality reduction was performed on the concatenated data set. After PMA stimulation, PD-L1 + cells were displayed 
based on the expression of 6 markers using t-SNE (t-distributed stochastic neighbor embedding) visualization. The axes (t-SNE1 and t-SNE2) show dimensionless 
values that were assigned to individual cells by the t-SNE algorithm, which places PD-L1 + MDSCs that have similar expression profiles close to one another. In Panel 
C, the intensity of the coloring is relative to the cell density of PD-L1 + MDSCs. In Panel D, the intensity of the coloring is relative to the expression of PD-L1 + MDSCs. 
MDSCs from pre- and post-immunotherapy have similar cell density and expression patterns that identify them as well conserved entities across biologic therapy. 
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